Nanofiltration of single plasma donations: feasibility study

Abstract

It is possible to apply a 75 + 35-nm filtration process to leucoreduced human plasma. This technology may have important future benefits in improving the quality and safety of plasma, by removing blood cell debris and infectious agents.

Cascade iodination: a novel method to enhance the safety and efficacy of therapeutic proteins

“…In this report, four of five patients achieved durable remission confirming the successful outcome using rituximab in refractory TTP recently reported by other investigators [5][6][7]. The dose and frequency of administration of rituximab in the current series is based on the experience in the treatment of non-Hodgkin's lymphoma.…”

“…The mechanism of cell killing is thought to be secondary to antibody-dependent cellular toxicity and complement activation. Suppression of autoreactive B cells may explain the sustained response attained when using rituximab in the treatment of lymphomas and autoimmune disorders [3,4].In this report, four of five patients achieved durable remission confirming the successful outcome using rituximab in refractory TTP recently reported by other investigators [5][6][7]. The dose and frequency of administration of rituximab in the current series is based on the experience in the treatment of non-Hodgkin's lymphoma.…”

“…The time to recovery of platelet counts in our patients is consistent with the results observed in patients with idiopathic thrombocytopenic purpura [4]. All patients in that study received rituximab in a dose and frequency similar to the current series.Because of the limited available experience in the treatment of TTP with rituximab, it is difficult to make direct comparison with the results obtained from other investigators [5][6][7]. For example, one patient with chronic relapsing TTP achieved a rather short remission with two doses and a sustained remission after four infusions of rituximab [6].…”

“…For example, one patient with chronic relapsing TTP achieved a rather short remission with two doses and a sustained remission after four infusions of rituximab [6]. In another case, full recovery of platelet count and durable remission was achieved after only two doses of rituximab [5]. Therefore, the number of doses of rituximab required to achieve response in patients with refractory TTP is worth addressing in future trials.…”

“…Because of the limited available experience in the treatment of TTP with rituximab, it is difficult to make direct comparison with the results obtained from other investigators [5][6][7]. For example, one patient with chronic relapsing TTP achieved a rather short remission with two doses and a sustained remission after four infusions of rituximab [6].…”